Giuseppe Curigliano, MD, discussed next steps following the HER2CLIMB study in HER2-positive breast cancer.
Giuseppe Curigliano, MD, PhD
Advertisement
Giuseppe Curigliano, MD PhD, is full professor of medical oncology at the University of Milano and chief of the Clinical Division of Early Drug Development at European Institute of Oncology, Milano, Italy.
Articles by Giuseppe Curigliano, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
